Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.67 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.67 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.67 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 2/20 | 0.53 |
| ▸ | ALPG | P10696 | 2/20 | 0.53 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8492186 | 0.90 | BCHE (0.72) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL17329389 | 0.85 | BCHE (0.57) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL14638914 | 0.83 | BCHE (0.67) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL19374547 | 0.83 | BCHE (0.67) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL8464091 | 0.83 | BCHE (0.82) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL4422048 | 0.83 | BCHE (0.67) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL7217435 | 0.81 | BCHE (0.60) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL22619945 | 0.80 | BCHE (1.00) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL14068347 | 0.80 | BCHE (0.72) | BCHETRPC3TRPC4TRPC5TSHR | |
| SCHEMBL2674051 | 0.80 | RAB9A (0.71) | BCHETRPC3TRPC4TRPC5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2734516-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Boehringer Ingelheim International GmbH (DE) | 2014-05-28 | — | — | EP | claimed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | claimed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220218839-A1 | SELECTIVE UV CROSSLINKING OF PEPTIDES AND FUNCTIONAL MOIETIES TO IMMUNOGLOBULINS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-07-14 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11116848-B2 | Selective UV crosslinking of peptides and functional moieties to immunoglobulins | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
| EP-2970440-B1 | SELECTIVE UV CROSSLINKING OF PEPTIDES AND FUNCTIONAL MOIETIES TO IMMUNOGLOBULINS | UNIV NOTRE DAME DU LAC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190328896-A1 | SELECTIVE UV CROSSLINKING OF PEPTIDES AND FUNCTIONAL MOIETIES TO IMMUNOGLOBULINS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2002050039-A1 | UREA AND URETHANE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
| WO-1999000390-A1 | NOVEL BENZIMIDAZOL TRICYCLIC DERIVATIVES, THEIR PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1999-01-07 | — | — | WO | disclosed |
| EP-0571253-B1 | Benzimidazole derivatives with antidiabetic and antiplatelet aggregation activity | ADIR (FR) | 1998-11-04 | — | — | EP | disclosed |
| US-5639756-A | ANTIDIABETIC AGENTS | ADIR ET COMPAGNIE (FR) | 1997-06-17 | — | — | US | disclosed |
| US-5623073-A | ANTIDIABETIC AGENT | ADIR ET COMPAGNIE (FR) | 1997-04-22 | — | — | US | disclosed |
| EP-0571253-A1 | Benzimidazole derivatives with antidiabetic and antiplatelet aggregation activity | ADIR ET COMPAGNIE (FR) | 1993-11-24 | — | — | EP | disclosed |
| US-4204069-A | 1-(5-BENZIMIDAZOYL)-2-ISOPROPYLAMINOETHANOL FROM ACETONE AND 1-(5-BENZIMIDAZOYL)-2-AMINOETHANOL | MERCK & CO., INC. (US) | 1980-05-20 | — | — | US | disclosed |
| US-4082847-A | 1-(5-BENZIMIDAZOLYL)-2-ISOPROPYLAMINOETHANOL, BRONCHODILATION, REDUCING INTRAOCULAR PRESSURE | MERCK & CO., INC. (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | BCHE 73/4885TRPC3 1891/4885TRPC4 498/4885 |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | BCHE 73/4885TRPC3 1891/4885TRPC4 498/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | BCHE 73/4885TRPC3 1891/4885TRPC4 498/4885 |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | BCHE 1042/4885TRPC3 1238/4885TRPC4 512/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | BCHE 73/4885TRPC3 1891/4885TRPC4 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.